Update on upcoming General Meeting

RNS Number : 6118R
NetScientific PLC
01 March 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

NetScientific plc

("NetScientific" or the "Company")

Update on upcoming General Meeting

 

NetScientific plc (AIM: NSCI) announces an update to the Company's circular and notice of general meeting to shareholders dated 15 February 2019 (the "Shareholder Circular") which notified shareholders of a general meeting to be held on 4 March 2019 (the "General Meeting").

The Company has received proxy forms from shareholders representing 30.04% per cent of the issued share capital of the Company instructing those shares to be voted against the resolution to be proposed at the General Meeting of the Company, as detailed in the Shareholder Circular, to cancel the admission of the shares to trading on AIM, re-register the Company as a private limited company and amend the Company's Current Articles to reflect the Company's new status as a private limited company (the "Resolution").

As such, the Board of NetScientific believes that the Resolution, would be defeated at the General Meeting.

Therefore, the Board proposes to adjourn the General Meeting.

Further announcements will be made as appropriate.

For more information, please contact:

NetScientific 

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

WH Ireland Limited (NOMAD, Financial Adviser and Broker)   

Chris Fielding / Jessica Cave / Chris Viggor

 

Tel: +44 (0)20 7220 1666

 

Consilium Strategic Communications                

Mary-Jane Elliott / Chris Welsh / Laura Thornton

NetScientific@consilium-comms.com

Tel: +44 (0)20 3709 5700

 

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOGCKDDDDBKDBNK
UK 100

Latest directors dealings